UPSTREAM BIO, INC. Long-term Line of Credit
UPSTREAM BIO, INC. (UPB) had Long-term Line of Credit of $200.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LineOfCredit · last filed 2026-03-26
- 2025-12-31: Long-term Line of Credit $200.00K.
- 2024-12-31: Long-term Line of Credit $200.00K.
- 2024-09-30: Long-term Line of Credit $200.00K.
| Period end | Long-term Line of Credit |
|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-03-26 |
| 2024-12-31 | $200.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $200.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |